Gilead Sciences and Lakefront Biotherapeutics Acquire Ouro Medicines
Gilead Sciences (GILD) and Lakefront Biotherapeutics have jointly acquired Ouro Medicines to further advance their pipeline of autoimmune treatments.
Results for "Ouro Medicines"
10 stories found
Galapagos NV and Gilead Sciences Announce Deal Related to Ouro Medicines Acquisition
Galapagos NV and Gilead Sciences have entered into an agreement concerning the acquisition of Ouro Medicines, signaling a new development in the pharmaceutical sector.
Gilead Acquires Ouro Medicines, Securing Rights to Keymed Antibody Drug
US biopharmaceutical company Gilead Sciences has agreed to acquire Ouro Medicines for up to US$2.18 billion, gaining rights to an antibody-based medicine for autoimmune diseases licensed from China’s Keymed Biosciences.
Gilead Sciences Acquires Ouro Medicines, Collaborates with Galapagos
Gilead Sciences has finalized its acquisition of autoimmune biotech company Ouro Medicines for up to $2 billion and will collaborate with Galapagos on the purchased assets.
Gilead and Lakefront Complete Ouro Medicines Acquisition
Gilead Sciences and Lakefront have successfully finalized the acquisition of Ouro Medicines, a move expected to impact their respective portfolios and market positions.
Gilead to Acquire Ouro Medicines in $2.18 Billion Deal to Expand Inflammation Pipeline
Gilead Sciences has announced its intention to acquire Ouro Medicines in a deal valued at $2.18 billion, aiming to expand its pipeline of treatments for inflammatory diseases.
Gilead Sciences to Acquire Ouro Medicines, Partner with Galapagos
Gilead Sciences has announced plans to acquire Ouro Medicines and will subsequently collaborate with Galapagos on the assets obtained through the purchase.
Galapagos NV and Gilead Sign Agreement on Ouro Medicines Assets
Galapagos NV announced it has signed an agreement with Gilead Sciences concerning assets related to Ouro Medicines. The details of the agreement were not immediately specified.
Gilead Sciences Acquires Ouro Medicines for $2.2 Billion to Boost T-Cell Therapy
Gilead Sciences is set to acquire biotech firm Ouro Medicines in a deal valued at $2.2 billion, marking its first TCE asset acquisition and aiming to boost its T cell therapy capabilities for autoimmune diseases.
Gilead Sciences Acquires Ouro Medicines, Partners with Galapagos
Gilead Sciences has announced its acquisition of Ouro Medicines and a subsequent collaboration with Galapagos on the newly purchased assets, as reported by the Wall Street Journal.